[{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"DiNAQOR AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"DiNA-001","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BioMarin Pharmaceutical \/ BioMarin Pharmaceutical ","highestDevelopmentStatusID":"5","companyTruncated":"BioMarin Pharmaceutical \/ BioMarin Pharmaceutical "},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BioMarin Pharmaceutical \/ BioMarin","highestDevelopmentStatusID":"1","companyTruncated":"BioMarin Pharmaceutical \/ BioMarin"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Fusogenix-formulated Gene Therapy","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"BioMarin Pharmaceutical \/ BioMarin","highestDevelopmentStatusID":"1","companyTruncated":"BioMarin Pharmaceutical \/ BioMarin"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"BMN 307","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Divestment","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Injectable\/Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Vosoritide","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec-rvox","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Vosoritide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Vosoritide","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"CAMP4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"regRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioMarin Pharmaceutical \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin Pharmaceutical \/ BioMarin Pharmaceutical"}]
Find Clinical Drug Pipeline Developments & Deals by BioMarin Pharmaceutical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
